SCHEMBL4346834

SCHEMBL4346834

COc1c(NC(=O)[C@@H]2CCC(=O)N2)ccc2[nH]nc(-c3ccc4ccccc4c3)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CDK4 P11802 1/20 0.38
CCNA2 P20248 1/20 0.38
CCND1 P24385 1/20 0.38
CDK2 P24941 1/20 0.38
CCND3 P30281 1/20 0.38
KDR P35968 1/20 0.38
POLB P06746 2/20 0.36
ALPL P05186 1/20 0.36
HPGDS O60760 1/20 0.35
SLC6A3 Q01959 2/20 0.35
SLC6A4 P31645 1/20 0.35
EGFR P00533 1/20 0.35
PARP1 P09874 2/20 0.35
LRRK2 Q5S007 1/20 0.35
BUB1 O43683 1/20 0.35
MAPK14 Q16539 1/20 0.35
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4346877 1.00 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2ACDK4CCNA2
SCHEMBL4335335 0.87 MEN1 (0.48) SMN1; SMN2MEN1KMT2AKDRPOLB
SCHEMBL4335978 0.87 GSK3B (0.47) CDK4CCNA2CCND1CDK2CCND3
SCHEMBL4335950 0.86 MEN1 (0.41) SMN1; SMN2MEN1KMT2APOLBHPGDS
SCHEMBL13198269 0.86 MEN1 (0.41) SMN1; SMN2MEN1KMT2APOLBHPGDS
SCHEMBL4329118 0.86 MEN1 (0.41) SMN1; SMN2MEN1KMT2APOLBHPGDS
SCHEMBL4345589 0.84 MAPK10 (0.44) SMN1; SMN2MEN1KMT2ASLC6A3PARP1
SCHEMBL4340656 0.84 MAPK10 (0.44) SMN1; SMN2MEN1KMT2ASLC6A3PARP1
SCHEMBL2865609 0.82 CDK4 (0.46) SMN1; SMN2CDK4CCNA2CCND1CDK2
SCHEMBL4335983 0.79 MEN1 (0.51) SMN1; SMN2MEN1KMT2ACDK4CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SMN1; SMN2 4812/4885MEN1 3782/4885KMT2A 2212/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SMN1; SMN2 4812/4885MEN1 3782/4885KMT2A 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.